Center-Authored Papers

Filters: Keyword is Acute Disease  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
Young Adult
Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, Petersdorf EW, Hsu KC.  2010.  Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation.. Blood. 115(15):3162-5. Abstract
Fang M, Storer BE, Estey EH, Othus M, Zhang L, Sandmaier BM, Appelbaum FR.  2011.  Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.. Blood. 118(6):1490-4. Abstract
McCune JS, Batchelder A, Guthrie KA, Witherspoon RP, Appelbaum FR, Phillips B, Vicini P, Salinger DH, McDonald GB.  2009.  Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.. Clinical pharmacology and therapeutics. 85(6):615-22. Abstract
Wölfl M, Rutebemberwa A, Mosbruger T, Mao Q, Li H-mei, Netski D, Ray SC, Pardoll D, Sidney J, Sette A et al..  2008.  Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire.. Journal of immunology (Baltimore, Md. : 1950). 181(9):6435-46. Abstract
Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B et al..  2009.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 113(26):6558-66. Abstract
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Flowers MED, Inamoto Y, Carpenter PA, Lee SJ, Kiem H-P, Petersdorf EW, Pereira S, Nash RA, Mielcarek M, Fero ML et al..  2011.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.. Blood. 117(11):3214-9. Abstract
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J et al..  2012.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.. Blood. 119(1):296-307. Abstract
Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ et al..  2014.  Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.. Blood. 124(22):3221-7;quiz3335. Abstract
Mielcarek M, Storer BE, Boeckh MJ, Carpenter PA, McDonald GB, Deeg HJ, Nash RA, Flowers MED, Doney K, Lee SJ et al..  2009.  Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.. Blood. 113(13):2888-94. Abstract
Gutman JA, Leisenring WM, Appelbaum FR, Woolfrey AE, Delaney C.  2009.  Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(9):1122-9. Abstract
Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B et al..  2010.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 116(5):702-10. Abstract
Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, McSweeney P, Niederwieser D, Bruno B, Storb R et al..  2010.  Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.. British journal of haematology. 150(2):170-8. Abstract
X-Linked Inhibitor of Apoptosis Protein
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW et al..  2009.  Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4741-6. Abstract
Whole-Body Irradiation
Rezvani AR, Norasetthada L, Gooley TA, Sorror ML, Bouvier ME, Sahebi F, Agura E, Chauncey TR, Maziarz RT, Maris M et al..  2008.  Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.. British journal of haematology. 143(3):395-403. Abstract
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Gyurkocza B, Cao TM, Storb R, Lange T, Leisenring WM, Franke GN, Sorror ML, Hoppe R, Maloney DG, Negrin RS et al..  2009.  Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(10):1314-22. Abstract
Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, Martin PJ, Mitchell D, Press OW, Storb R et al..  1999.  Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.. Blood. 94(4):1237-47. Abstract
Mielcarek M, Burroughs L, Leisenring W, Diaconescu R, Martin PJ, Sandmaier BM, Maloney DG, Maris MB, Chauncey TR, Shizuru JA et al..  2005.  Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.. British journal of haematology. 129(3):381-91. Abstract
McCune JS, Batchelder A, Guthrie KA, Witherspoon RP, Appelbaum FR, Phillips B, Vicini P, Salinger DH, McDonald GB.  2009.  Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.. Clinical pharmacology and therapeutics. 85(6):615-22. Abstract
Rezvani AR, Storer BE, Guthrie KA, Schoch GH, Maloney DG, Sandmaier BM, Storb R.  2015.  Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(1):105-12. Abstract
Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ et al..  2009.  Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.. Blood. 114(27):5444-53. Abstract
Virus Replication
Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H et al..  2015.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.. Nature. 517(7534):381-5. Abstract
Virus Latency
Wölfl M, Rutebemberwa A, Mosbruger T, Mao Q, Li H-mei, Netski D, Ray SC, Pardoll D, Sidney J, Sette A et al..  2008.  Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire.. Journal of immunology (Baltimore, Md. : 1950). 181(9):6435-46. Abstract
Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H et al..  2015.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.. Nature. 517(7534):381-5. Abstract